HK1117381A1 - Granular preparation containing biguanide compound - Google Patents

Granular preparation containing biguanide compound

Info

Publication number
HK1117381A1
HK1117381A1 HK08107710.6A HK08107710A HK1117381A1 HK 1117381 A1 HK1117381 A1 HK 1117381A1 HK 08107710 A HK08107710 A HK 08107710A HK 1117381 A1 HK1117381 A1 HK 1117381A1
Authority
HK
Hong Kong
Prior art keywords
preparation containing
granular preparation
biguanide compound
containing biguanide
compound
Prior art date
Application number
HK08107710.6A
Other languages
English (en)
Inventor
Yasushi Ochiai
Yasuhiro Matsui
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Publication of HK1117381A1 publication Critical patent/HK1117381A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
HK08107710.6A 2005-04-26 2008-07-14 Granular preparation containing biguanide compound HK1117381A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005127360 2005-04-26
PCT/JP2006/308711 WO2006118137A1 (ja) 2005-04-26 2006-04-26 ビグアナイド系薬物を含有する粒状製剤

Publications (1)

Publication Number Publication Date
HK1117381A1 true HK1117381A1 (en) 2009-01-16

Family

ID=37307936

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08107710.6A HK1117381A1 (en) 2005-04-26 2008-07-14 Granular preparation containing biguanide compound

Country Status (14)

Country Link
US (1) US8192761B2 (xx)
EP (2) EP1878426B1 (xx)
JP (1) JP5084499B2 (xx)
KR (1) KR20080007371A (xx)
CN (1) CN101198319B (xx)
CA (1) CA2607419C (xx)
CY (1) CY1110756T1 (xx)
DE (1) DE602006014958D1 (xx)
ES (1) ES2343432T3 (xx)
HK (1) HK1117381A1 (xx)
PL (1) PL1878426T3 (xx)
PT (1) PT1878426E (xx)
SI (1) SI1878426T1 (xx)
WO (1) WO2006118137A1 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
JP5315056B2 (ja) * 2006-10-25 2013-10-16 大日本住友製薬株式会社 固結抑制粒状製剤
US20080107787A1 (en) * 2006-11-02 2008-05-08 The Coca-Cola Company Anti-Diabetic Composition with High-Potency Sweetener
BRPI0917026A2 (pt) * 2008-08-08 2016-02-16 Mcneil Ppc Inc uso de sucralose como agente granulador
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
WO2011154975A2 (en) 2010-06-08 2011-12-15 Cadila Healthcare Limited Pharmaceutical compositions of metformin
ES2556985T3 (es) 2011-01-11 2016-01-21 Capsugel Belgium Nv Nuevas cápsulas duras que comprenden pululano
CA3059527A1 (en) 2017-04-14 2018-10-18 Capsugel Belgium Nv Pullulan capsules
BR112019021396A2 (pt) 2017-04-14 2020-04-28 Capsugel Belgium Nv processo para fabricação de pululano
WO2020060674A1 (en) * 2018-09-20 2020-03-26 Kci Licensing, Inc. Super-absorbent, low trauma, advanced wound dressing

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JP3583166B2 (ja) * 1994-06-27 2004-10-27 興和株式会社 損傷皮膚修復用粉末製剤
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US6413541B1 (en) * 1999-01-13 2002-07-02 Dainippon Pharmaceutical Co., Ltd. Disintegrating tablet in oral cavity and production thereof
AU3536299A (en) * 1998-04-29 1999-11-16 Sumitomo Pharmaceuticals Company, Limited Oral formulation comprising biguanide and an organic acid
JP4606582B2 (ja) 1998-04-29 2011-01-05 大日本住友製薬株式会社 ビグアナイド系薬物の内服製剤
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
SK2102003A3 (en) * 2000-08-07 2003-08-05 Ranbaxy Signature Llc Liquid formulation of metformin
JP2002241267A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
JP4438268B2 (ja) * 2001-03-07 2010-03-24 大日本住友製薬株式会社 薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤
DE60211769T2 (de) * 2001-03-07 2007-05-24 Dainippon Sumitomo Pharma Co., Ltd. Verfahren zur Herstellung von Arzneistoffgranulatkörnern, die Arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische Zubereitungen
BR0213079A (pt) * 2001-09-28 2004-11-09 Sun Pharmaceutical Ind Ltd Forma de dosagem para o tratamento da diabetes mellitus
WO2003099214A2 (en) 2002-05-23 2003-12-04 Andrx Corporation Biguanide formulations
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
EP1646374A1 (en) * 2003-06-16 2006-04-19 Ranbaxy Laboratories, Ltd. Extended-release tablets of metformin
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
JP2005068116A (ja) * 2003-08-28 2005-03-17 Toa Eiyo Ltd 塩酸メトホルミンを含有する速放性フィルムコーティング錠剤
JP2005139173A (ja) * 2003-10-17 2005-06-02 Medorekkusu:Kk ビグアナイド系薬剤を含有するゼリー製剤
EP1674088A4 (en) * 2003-10-17 2009-04-15 Medrx Co Ltd Grape-based preparation containing a biguaneid drug
JP4814636B2 (ja) 2004-01-29 2011-11-16 大日本住友製薬株式会社 ビグアナイド系薬物の内服製剤

Also Published As

Publication number Publication date
WO2006118137A1 (ja) 2006-11-09
EP1878426A1 (en) 2008-01-16
EP1878426B1 (en) 2010-06-16
KR20080007371A (ko) 2008-01-18
DE602006014958D1 (de) 2010-07-29
PT1878426E (pt) 2010-06-28
SI1878426T1 (sl) 2010-09-30
PL1878426T3 (pl) 2010-11-30
JPWO2006118137A1 (ja) 2008-12-18
CN101198319B (zh) 2012-08-01
EP1878426A4 (en) 2008-12-24
CY1110756T1 (el) 2015-06-10
CN101198319A (zh) 2008-06-11
US8192761B2 (en) 2012-06-05
EP2204169A1 (en) 2010-07-07
CA2607419C (en) 2014-06-17
US20090130215A1 (en) 2009-05-21
ES2343432T3 (es) 2010-07-30
JP5084499B2 (ja) 2012-11-28
CA2607419A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
HK1117381A1 (en) Granular preparation containing biguanide compound
GB0510139D0 (en) Novel compounds B1
GB0500492D0 (en) Compound
GB0513702D0 (en) Compound
GB0506133D0 (en) Compound
EP1876179A4 (en) THIENOPYRIMIDONVERBINDUNGEN
GB0520955D0 (en) Compound
EP1961741A4 (en) M-CARBAZOLYLPHENYL COMPOUNDS
GB0502310D0 (en) Compounds
GB0502299D0 (en) Compounds
GB0512429D0 (en) Novel compound
AP2007004220A0 (en) Motilide compounds
GB0525323D0 (en) Compound
EP1907385A4 (en) LINKS
GB0509829D0 (en) Compound
TWI367727B (en) Granular sucralose
GB0616173D0 (en) Compound
GB0501985D0 (en) Compounds
GB0504998D0 (en) Antimicrobial compounds
GB0524685D0 (en) Compound
GB0516378D0 (en) Compound
EP1867650A4 (en) HYDROXYMETHYLBORVERBINDUNGEN
GB0501984D0 (en) Compounds
KZ19273A (en) Compound container
EP1961756A4 (en) NEW BISBORNET CONNECTION

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170426